American Tinnitus Association Announces New Board Leadership
25 juin 2019 09h15 HE
|
American Tinnitus Association
Vienna, Virginia, June 25, 2019 (GLOBE NEWSWIRE) -- The American Tinnitus Association (ATA) Board of Directors has elected Dr. Jill Meltzer as Chair and John Minnebo as Vice-Chair for two-year...
Otonomy to Present at the Raymond James Life Sciences and MedTech Conference
12 juin 2019 08h00 HE
|
Otonomy, Inc.
SAN DIEGO, June 12, 2019 (GLOBE NEWSWIRE) -- Otonomy, Inc. (NASDAQ: OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today announced that...
May is Mental Health Awareness Month: American Tinnitus Association Highlights Using Cognitive Behavioral Therapy to Manage Tinnitus
29 mai 2019 12h51 HE
|
American Tinnitus Association
Vienna, Virginia, May 29, 2019 (GLOBE NEWSWIRE) -- The American Tinnitus Association (ATA) has released a Conversations in Tinnitus “CBT to Reclaim Your Life,” podcast with Bruce Hubbard, PhD, to...
May is Mental Health Awareness Month: American Tinnitus Association Highlights Using Cognitive Behavioral Therapy to Manage Tinnitus
29 mai 2019 09h35 HE
|
American Tinnitus Association
Vienna, Virginia, May 29, 2019 (GLOBE NEWSWIRE) -- The American Tinnitus Association (ATA) has released a Conversations in Tinnitus “CBT to Reclaim Your Life,” podcast with Bruce Hubbard, PhD, to...
Otonomy to Participate in SunTrust Robinson Humphrey Life Sciences Summit
01 mai 2019 07h30 HE
|
Otonomy, Inc.
SAN DIEGO, May 01, 2019 (GLOBE NEWSWIRE) -- Otonomy, Inc. (NASDAQ: OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today announced...
Otonomy to Report First Quarter 2019 Financial Results and Provide Corporate Update
29 avr. 2019 16h05 HE
|
Otonomy, Inc.
SAN DIEGO, April 29, 2019 (GLOBE NEWSWIRE) -- Otonomy, Inc. (NASDAQ: OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today announced it...
Otonomy Initiates Phase 1/2 Clinical Trial of OTO-313 in Tinnitus
11 avr. 2019 07h30 HE
|
Otonomy, Inc.
SAN DIEGO, April 11, 2019 (GLOBE NEWSWIRE) -- Otonomy, Inc. (NASDAQ: OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today announced the...
Otonomy to Participate in Two Upcoming Investor Conferences
05 mars 2019 07h30 HE
|
Otonomy, Inc.
SAN DIEGO, March 05, 2019 (GLOBE NEWSWIRE) -- Otonomy, Inc. (NASDAQ: OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today announced that...
Otonomy Reports Fourth Quarter and Full Year 2018 Financial Results and Provides Corporate Update
04 mars 2019 16h18 HE
|
Otonomy, Inc.
OTIVIDEX™ Phase 3 trial in Ménière’s disease on track for results in first half 2020 OTO-313 Phase 1/2 trial in tinnitus expected to start in second quarter of 2019OTO-413 Phase 1/2 trial in hearing...
Otonomy to Report Fourth Quarter and Full Year 2018 Financial Results and Provide Corporate Update
25 févr. 2019 16h05 HE
|
Otonomy, Inc.
SAN DIEGO, Feb. 25, 2019 (GLOBE NEWSWIRE) -- Otonomy, Inc. (NASDAQ: OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today announced it...